Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
In both the natriuretic peptide and renin-angiotensin systems, peptidases play an important role in the inactivation or activation of the system. Angiotensin-converting enzyme is responsible for the conversion of angiotensin I to angiotensin II, while neutral endopeptidase is one of the pathways involved in the degradation of the natriuretic peptides. The vasopeptidase inhibitors, which simultaneously inhibit neutral endopeptidase and angiotensin-converting enzyme, appear to offer distinct therapeutic advantages in treating hypertension, heart failure, and endothelial dysfunction.
Kubota
E
E
Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Studley Road, Heidelberg 3084, Victoria, Australia.
Dean
R G
RG
Hubner
R A
RA
Balding
L C
LC
Johnston
C I
CI
Burrell
L M
LM
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000187:drug effects*; D006321:Heart / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000209:etiology; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D012084:Renin-Angiotensin System / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D015260:Neprilysin